Pharmacological discrimination between gamma-aminobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes

A Gemignani, P Paudice, G Bonanno and M Raiteri

Institute of Pharmacology and Pharmacognosy, University of Genoa, Italy.

The gamma-aminobutyric acid (GABA)B receptors modulating the depolarization-evoked release of somatostatin (SRIF) or cholecystokinin (CCK) from superfused rat cerebrocortical synaptosomes have been characterized pharmacologically. GABA inhibited the 15 mM KCl-evoked overflow of both SRIF and CCK; the EC50 values were 1.3 microM and 1.4 microM, respectively. The GABAB receptor agonist (-)-baclofen also diminished the release of SRIF (EC50 = 1.9 microM) and CCK (EC50 = 2.6 microM). The novel compound CGP 47656, a highly selective GABAB receptor ligand, inhibited the release of SRIF, with its affinity and efficacy being similar to those of GABA or (-)-baclofen; however, the compound was unable to affect CCK release even when tested at 300 microM. The GABAB receptor antagonist phaclofen prevented, with identical affinities, the effects of (-)-baclofen on SRIF (pKb = 4.9) and CCK (pKb = 4.8) release. The same was true for CGP 35348, another GABAB receptor antagonist, which blocked (-)-baclofen with a pKb value of 6.1 at both the GABAB receptors regulating SRIF and CCK release. The effects of (-)-baclofen were also counteracted by the novel GABAB receptor antagonist CGP 52432. However, the affinity of the drug at the GABAB receptors modulating SRIF release (pKb = 6.2) was about 30-fold lower than that at the receptors regulating CCK release (pKb = 7.6). The data suggest that the GABAB receptors situated on nerve terminals releasing SRIF and CCK display pharmacological heterogeneity and may represent different subtypes of GABAB receptors.

Volume 46, Issue 3, pp. 558-562, 09/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Raiteri Functional pharmacology in human brain. Pharmacol. Rev., June 1, 2006; 58(2): 162 - 193. [Abstract] [Full Text] [PDF]

				B. Bettler, K. Kaupmann, J. Mosbacher, and M. Gassmann Molecular Structure and Physiological Functions of GABAB Receptors Physiol Rev, July 1, 2004; 84(3): 835 - 867. [Abstract] [Full Text] [PDF]

				L. P. Carter, A. W. Unzeitig, H. Wu, W. Chen, A. Coop, W. Koek, and C. P. France The Discriminative Stimulus Effects of {gamma}-Hydroxybutyrate and Related Compounds in Rats Discriminating Baclofen or Diazepam: The Role of GABAB and GABAA Receptors J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 540 - 547. [Abstract] [Full Text] [PDF]

				N. G. Bowery, B. Bettler, W. Froestl, J. P. Gallagher, F. Marshall, M. Raiteri, T. I. Bonner, and S. J. Enna International Union of Pharmacology. XXXIII. Mammalian gamma -Aminobutyric AcidB Receptors: Structure and Function Pharmacol. Rev., June 1, 2002; 54(2): 247 - 264. [Abstract] [Full Text] [PDF]

				S. J. Enna A GABAB Mystery: The Search for Pharmacologically Distinct GABAB Receptors Mol. Interv., October 1, 2001; 1(4): 208 - 218. [Abstract] [Full Text] [PDF]

				M. Marcoli, S. Scarrone, G. Maura, G. Bonanno, and M. Raiteri A Subtype of the gamma -Aminobutyric AcidB Receptor Regulates Cholinergic Twitch Response in the Guinea Pig Ileum J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 42 - 47. [Abstract] [Full Text]

				J. C. Rekling, G. D. Funk, D. A. Bayliss, X.-W. Dong, and J. L. Feldman Synaptic Control of Motoneuronal Excitability Physiol Rev, April 1, 2000; 80(2): 767 - 852. [Abstract] [Full Text] [PDF]

				N. G. Bowery and S. J. Enna gamma -Aminobutyric AcidB Receptors: First of the Functional Metabotropic Heterodimers J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 2 - 7. [Abstract] [Full Text]

				K. Yamada, B. Yu, and J. P. Gallagher Different Subtypes of GABAB Receptors Are Present at Pre- and Postsynaptic Sites Within the Rat Dorsolateral Septal Nucleus J Neurophysiol, June 1, 1999; 81(6): 2875 - 2883. [Abstract] [Full Text] [PDF]